fbpx

COVID-19 Research Project in India with OmicsBox Support

COVID-19 Research Project in India with OmicsBox Support

BioBam Supported Project – with OmicsBox.

Researchers:

Project:

The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pushed the entire world on a halt with the largest lockdown of our times. A total numbers of infected cases are 1,938,863 with 120,871 deaths (source: https://covid19stats.live/, by 14-April 2020).There is a massive urge of clinical solutions like vaccine development. Corona viruses have smaller genome of 30 kb size with 24 proteins. Yet several proteins are not properly annotated and characterised and often named as ORFs or CoV proteins. This hinders development of protein based vaccine development. Hence, there are needs for extensive re-annotation and characterisation of all proteins and their motives. The Computational Genome Biology Lab at Institute of Bioinformatics, Bangalore, India started now a genome-wide characterisations of CoV proteins and their motifs for potential roles as directed therapeutics. This study will assist in decision making for future vaccine development for COVID-19.

OmicsBox is a complete suite for genome analyses and annotations. It will assist us in rapid annotation and re-annotation of several CoVs and coming up for highly annotated solution for designing peptides.

This project is now supported with free access to all OmicsBox resources, including all modules and unlimited cloud computation.

OmicsBox supports COVID-19 projects
Share on facebook
Share on twitter
Share on linkedin

Blog Categories:

News

Releases, Media, Announcements, etc.

Use Cases, Reviews, Tutorials

Product Tutorial, Quickstarts, New Features, etc.

Video Tutorials

Helpful Features, Tips and Tricks

Tips And Tricks

Mini-tutorials for common use-cases and to address frequently asked questions FAQs

Most Popular:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print